It's been a mediocre week for Stemline Therapeutics, Inc. (NASDAQ:STML) shareholders, with the stock dropping 19% to US$4.06 in the week since its latest annual results. Revenues came in at US$43m, in ...
If you're interested in Stemline Therapeutics, Inc. (NASDAQ:STML), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your ...
Acquisition of Stemline establishes Menarini’s presence in the U.S. biopharmaceutical oncology market Ivan Bergstein, M.D., Chairman, CEO and Founder of Stemline, said, “Joining Menarini represents a ...
Stemline Therapeutics Inc (NASDAQ:STML) is one of the biggest stories in the biotechnology space this week. The company has fallen foul of accusations that it held back pertinent information from ...
Menarini subsidiary Stemline Therapeutics has won FDA approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs that provide a new form of hormonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results